Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05200481
Title Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Intergroupe Francophone de Cancerologie Thoracique
Indications

lung non-small cell carcinoma

Therapies

Brigatinib + Carboplatin + Pemetrexed Disodium

Brigatinib

Age Groups: adult | senior
Covered Countries FRA

Additional content available in CKB BOOST